$94.62
-4.14-4.19%
Last update: Nov 10, 2:52 PM
Kiniksa Pharmaceuticals International PLC
KNSANASDAQ
Kiniksa Pharmaceuticals International rose 150.0% from $39.50 to a 1-year high of $98.76, ahead of the S&P 500's +10.5%. Its worst day was Feb 24 (−8.2%), and its low came Jan 15 at $37.92.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Kiniksa Pharmaceuticals International closed at its lowest level of the year, 4.0% below where the year started.
−4.1% · S&P 500 +0.3%
EPS of $0.17 missed the $0.35 estimate on $202.1M revenue (est. $200.9M); FY revenue guidance of $900.0M–$920.0M against the $904.8M consensus.
Story events cover the past 12 months · Times ET
−8.2%, the year's worst day · S&P 500 +0.7%
EPS of $0.27 beat the $0.16 estimate on $214.3M revenue (est. $205.6M); FY revenue guidance of $930.0M–$945.0M against the $912.7M consensus.
+23.5% · S&P 500 −0.5%
EPS of $0.30 beat the $0.30 estimate on $243.6M revenue (est. $226.7M); FY revenue guidance of $980.0M–$995.0M against the $940.1M consensus.
+25.0%, the year's best day · S&P 500 +0.2%
EPS of $0.56 beat the $0.33 estimate on $286.0M revenue (est. $260.4M); FY revenue guidance of $1.0B–$1.1B against the $995.9M consensus.
+22.2% · S&P 500 +0.6%
Where it ended: a 1-year high close of $98.76 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 23, 2027 (EPS est. $0.26, revenue est. $306.0M).
Nothing in the past 12 months.
All KNSA dividend historyReplay the year: the line draws itself and stops at each of the 5 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KNSA and SPY from Benzinga historical bars. Not investment advice.
